Loading company
$2.14-7.0%Nov 13 close
Next earnings: December 21, 2026
Figures through July 31, 2026, from the 10-Q filed September 14, 2026
Past performance
- 1W
- -24.4%
- 1M
- -29.1%
- 3M
- +3.9%
- 6M
- +12.0%
- 1Y
- -30.3%
$2.14-7.0%Nov 13 close
Next earnings: December 21, 2026
Figures through July 31, 2026, from the 10-Q filed September 14, 2026
HeartSciences Inc. is scheduled to report next on December 21, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending July 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toJul 31, 2026 | 3 months toJul 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2.1K | $1.9K | +10.53% |
| Profit | -$3.2M | -$2.1M | -54.37% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
HeartSciences Inc. has no earnings call transcript available.
“This has been a period of significant change for the Company. The proposed combination with Fortitude is expected to give our shareholders exposure to a business that is a meaningful participant in the Zcash ecosystem. In our view, it represents a significant opportunity for shareholders and the transaction continues to move toward closing,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
HeartSciences is a healthcare information technology company advancing the use of ECG/EKGs through the integration of artificial intelligence. HeartSciences’ MyoVista Insights™ Platform is a cloud-native, vendor- and device-agnostic ECG management system designed to modernize ECG workflows and improve clinical efficiency and decision-making. The platform’s AI-ECG marketplace is designed to deliver AI-ECG algorithms into clinical workflows across a health system’s existing ECG equipment.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from HeartSciences Inc.’s Item 2.02 8-K filed September 15, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.